Tariffs, FDA Upheaval Drive New Wave of U.S. Biomanufacturing Projects
Rising tariffs and regulatory shake-ups are reshaping how drugmakers plan, design and deliver the next generation of U.S. biomanufacturing facilities.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief